Ketamine Improved Chronic Pain for Patients with Cancer Following Surgery
Drug Topics
OCTOBER 31, 2024
Researchers conducted a systematic review of randomized trials to determine the efficacy of ketamine for patients with cancer.
Drug Topics
OCTOBER 31, 2024
Researchers conducted a systematic review of randomized trials to determine the efficacy of ketamine for patients with cancer.
STAT
OCTOBER 31, 2024
Teva Pharmaceutical, the world’s largest generic drugmaker, was fined $503 million by European antitrust regulators for delaying competition to a blockbuster multiple sclerosis medicine. The European Commission found the company had artificially extended the patent protection of Copaxone and systematically spread misleading information about a rival product.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
OCTOBER 31, 2024
Presenters at the National Community Pharmacists Association 2024 Annual Convention and Expo discussed workflow and the future of pharmacy as a patient destination.
Fierce Pharma
OCTOBER 31, 2024
Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | The FDA this week revised its shortage list to note that the.25 mg starter dose of Novo’s semaglutide-based obesity med Wegovy is now available in the U.S.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmacy Times
OCTOBER 31, 2024
Incorporating the teach-back method and providing patient handouts expand health knowledge.
STAT
OCTOBER 31, 2024
Barely 12 years after the publication of the first papers unveiling CRISPR-Cas9, a powerful enzyme for editing DNA, sickle cell patients are now receiving the first approved CRISPR-based medicine, Casgevy. Hundreds of patients with other inherited diseases, cancers, and chronic bacterial and viral infections are enrolled in clinical trials testing other CRISPR treatments.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
OCTOBER 31, 2024
Two generic drugmakers, Apotex and Heritage Pharmaceuticals, have agreed to pay a combined $49 million to settle allegations they fixed prices on numerous medicines, the first such agreements since state attorneys general began probing price-fixing in the generics industry a decade ago. In 2016, a number of states filed what eventually became the first in a trio of lawsuits against many of the largest generic companies for allegedly coordinating efforts to fix and maintain prices for dozens of m
Fierce Healthcare
OCTOBER 31, 2024
Making true progress toward value-based care requires buy-in and understanding from physicians — and for them to be willing to find common ground with insurers for collaborating. | UnitedHealth Group partnered with the University of Minnesota's medical school to launch a four-week elective course that exposes fourth-year medical students to value-based care and has them working in person with Optum clinicians.
STAT
OCTOBER 31, 2024
Of 104 reports of supply chain issues with dozens of drugs, meaningful shortages were 40% less likely to occur in Canada than in the U.S., a new study found, and the difference was largely attributed to the approach taken by the Canadian government to the problem. Between 2017 and 2021, regulators in the U.S. and Canada received the same number of reports about actual or potential shortages for the same 96 medicines.
Fierce Healthcare
OCTOBER 31, 2024
Optum Rx is rolling out a slate of new programs that seek to support independent pharmacies in managing costs and more complex patient needs. | Optum Rx is rolling out a slate of new programs that seek to support independent pharmacies in managing costs and more complex patient needs.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
OCTOBER 31, 2024
Following lung cancer diagnosis, adjusting lifestyle habits can improve treatment responses.
STAT
OCTOBER 31, 2024
After spending decades fixated on a single hypothesis, Alzheimer’s researchers are increasingly searching for new ways to combat the devastating neurologic disease. One such approach — precisely targeting the brain with magnetic pulses — got a boost when mid-stage trial data was presented Thursday. Scientists reported that patients with mild or moderate Alzheimer’s who received the therapy, known as transcranial magnetic stimulation (TMS), experienced a 44% slowing in
Pharmaceutical Commerce
OCTOBER 31, 2024
With today's pharmacy landscape shaken by unprecedented and wider disruption to healthcare support and delivery, community and independent entities strive to remain an integral cog in the mix.
Fierce Pharma
OCTOBER 31, 2024
While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional fright surrounding another staple product took the spotlight during the co | Despite the China growth woes, Merck is still confident it can achieve its $11 billion sales goal for the HPV vaccine by 2030.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Drug Topics
OCTOBER 31, 2024
Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
Fierce Pharma
OCTOBER 31, 2024
With U.S. | With U.S. sales of $392 million in the third quarter, Regeneron’s high-dose version of Eylea is closing in on blockbuster sales in its first full year on the market. The bad news for the company, however, is that while sales from Eylea HD increased by 29% sequentially, this didn't translate to a similar bump in overall U.S. revenue for the Eylea family of eye medications.
BioPharm
OCTOBER 31, 2024
The Novo Nordisk Foundation has committed DKK 600 million (US$87.4 million) towards the initial costs of the center housing the new supercomputer, which has the potential to accelerate drug discovery innovation.
Fierce Healthcare
OCTOBER 31, 2024
The Cigna Group reported $739 million in profit for the third quarter, a figure that accounts for a $1 billion after-tax investment loss tied to VillageMD. | The Cigna Group reported $739 million in profit for the third quarter, a figure that accounts for a $1 billion after-tax investment loss tied to VillageMD.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
OCTOBER 31, 2024
Effective language training for healthcare teams within the NHS is crucial for providing quality care and communication with diverse patient populations. Learn why it is essential for healthcare professionals.
Fierce Healthcare
OCTOBER 31, 2024
Medicare Advantage’s popularity is associated with lower total Medicare spending, a new report from Elevance Health finds. | Elevance Health researchers might have an explanation for lower-than-expected Medicare spending: the proliferation of Medicare Advantage plans.
pharmaphorum
OCTOBER 31, 2024
Compass Pathways will cut its headcount by 30% as it defers phase 3 readouts for its psychedelic therapy for treatment-resistant depression.
Pharmacy Times
OCTOBER 31, 2024
Further efforts may be required to urge eligible members of the public to get screened for lung cancer.
pharmaphorum
OCTOBER 31, 2024
The European Commission has delivered a hefty fine to Teva for abusing a dominant position in multiple sclerosis by artificially extending the patent protection for former blockbuster Copaxone.
Pharmacy Times
OCTOBER 31, 2024
Targeted therapies, CDK4/6 inhibitors, and precision medicine are improving outcomes for patients with high-risk and metastatic disease.
pharmaphorum
OCTOBER 31, 2024
Our latest round-up of financings in the biotech sector features Alpha-9 Oncology, Axonis, Kivu Bio, SynOx, Agomab, and Blue Earth Therapeutics.
Pharmacy Times
OCTOBER 31, 2024
A patient with BPDCN finds her champion.
Fierce Healthcare
OCTOBER 31, 2024
The relationship between health systems and health plans has historically been fraught with tension, as each side tries to outmaneuver the other. | The relationship between health systems and health plans has historically been fraught with tension, as each side tries to outmaneuver the other. The latest secret weapon each side has been deploying? Artificial intelligence.
Pharmacy Times
OCTOBER 31, 2024
The simultaneous doses of both vaccines compared with individual RZV and quadrivalent high-dose inactivated influenza vaccine (HD-IIV4, Fluzone; Sanofi) had similar overall safety findings.
pharmaphorum
OCTOBER 31, 2024
Lexeo reveals "promising" early data for gene therapy for APOE4-associated Alzheimer's, but shares in the biotech fall.
Pharmacy Times
OCTOBER 31, 2024
Patients with hereditary angioedema who received sebetralstat earlier had faster complete resolution of their attacks.
pharmaphorum
OCTOBER 31, 2024
Septerna's protracted IPO on the Nasdaq has finally reached its conclusion, with the final amount raised by the GPCR-focused biotech above $331m
PharmaVoice
OCTOBER 31, 2024
Pfizer, J&J, Biogen and Novartis are banking on new products to make up for maturing blockbusters, but future growth is not guaranteed.
Pharmacy Times
OCTOBER 31, 2024
Although patients hope for reduced costs, Pharma’s reaction to the IRA remains to be seen.
Let's personalize your content